BBIO

BridgeBio Pharma, Inc.

NasdaqGSUSDEQUITY DELAYED

81.50

▼ 1.44 (1.74%)

MARKET · —

Price

Open

83.99

Prev close

82.94

Day high

83.37

Day low

81.37

Volume

1.74M

Market cap

—

P/E (TTM)

—

52W range

46.81 – 93.42

Trailing performance

Price return · vs SPY

Returnvs SPY

+2.05% +3.4%

-1.72% -5.5%

+15.96% +12.9%

+19.61% +8.5%

YTD

+6.55% -5.7%

+66.73% +46.7%

+173.49% +99.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

82.45

-1.16% from price

SMA 20

82.56

-1.29% from price

SMA 50

78.67

+3.60% from price

SMA 100

74.54

+9.33% from price

SMA 200

73.17

+11.38% from price

EMA 12

82.33

-1.01% from price

EMA 26

81.60

-0.12% from price

EMA 50

79.29

+2.78% from price

RSI (14)

50.0

Neutral

MACD (12,26,9)

0.73

Hist -0.37

ATR (14)

2.90

3.56% of price

Realised vol 30D

28.4%

Annualised

Bollinger upper

85.93

20, 2σ

Bollinger lower

79.20

20, 2σ

50 / 200 cross

Golden

78.67 vs 73.17

Trend bias

Above 200

+11.38%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.15

More volatile than market

Correlation to SPY

0.31

Loosely linked

Realised vol 30D

28.4%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-20.2%

Peak to trough

Max drawdown 5Y

-90.2%

Peak to trough

ATR 14

2.90

3.56% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 81.50

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

BBIO · links out to the publisher

Exelixis, Valaris, and 3 More Stocks See Action From Activist Investors Barrons.com · 16h ago Bridgebio Pharma Insider Sold Shares Worth $3,727,251, According to a Recent SEC Filing MT Newswires · 2d ago BridgeBio (BBIO) Q2 2026 Earnings Call Transcript Motley Fool · 3d ago BridgeBio Pharma (BBIO) Secured Two Priority Reviews For Rare Disease Drugs Simply Wall St. · 6d ago BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. Motley Fool · 8d ago BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says MT Newswires · 8d ago Update: BridgeBio Pharma Announces Secondary Offering of 5 Million Shares MT Newswires · 8d ago BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base GlobeNewswire · 8d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.